Las Vegas, NV -- (SBWIRE) -- 10/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Inovio Pharmaceuticals Inc (NYSEMKT: INO), Opko Health Inc. (NYSE:OPK), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)
Inovio Pharmaceuticals Inc (NYSEMKT: INO) managed to keep its gain at 6.25% on below -normal volume of 5.60M shares. The stock settled at $2.21 after floating in a range of $2.08 to $2.24. Its latest price has reached market capitalization of $419.69 million. Its 52-week range has been $0.44 to $3.03. Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases.
For How Long INO will fight for Profitability? Read This Trend Analysis report
Opko Health Inc. (NYSE:OPK) traded up on a volume of 5.34 million, higher than its standard daily volume. Shares have gained 1.84% to $9.97. Over the last twelve months, the stock has gained 138.52% and faced a worst price of $4.20. Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics.
For How Long OPK’s Gloss will Attract Investors? Find out via this report
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) settled -2.02% lower at $4.84 on below -normal volume of 5.20M shares during the last trading day. The stock has its 12-month high at $11 and 52-week low price was $4.87. It traded in a range of $4.83 to $4.95 during the last trading day. Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.
Will ARNA Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, MannKind Corporation (NASDAQ:MNKD) was down on low volume, trading at a volume of 4.99M versus its average daily volume of 5.28 million shares. At $5.38, the stock has attained market capitalization of 1.62 billion. MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States.
Why Should Investors Buy MNKD After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)